Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers

Abstract

Small-molecule BRAF inhibitors (e.g., vemurafenib and dabrafenib) and MEK (MAPK/ERK) kinases inhibitors (e.g., trametinib) have distinctly improved the survival of patients suffering from BRAF-mutant cancers such as melanomas. However, the emergence of resistance to BRAF and MEK inhibitor-based melanoma therapy, as well as the reduced sensitivity of other BRAF-mutant cancers such as CRC, poses a considerable clinical problem. For instance, the reactivation of MAPK/ERK signaling hampering cell death induction mechanisms was responsible for BRAF inhibitor resistance, which can be correlated with distinct post-translational and epigenetic processes. Histone deacetylases (HDACs) are prominent epigenetic drug targets and some HDAC inhibitors have already been clinically approved for the therapy of various blood cancers. In addition, several HDACs were identified, which also play a crucial role in the drug resistance of BRAF-mutant cancers. Consequently, inhibition of HDACs was described as a promising approach to overcome resistance. This review summarizes the influence of HDACs (Zn²⁺-dependent HDACs and NAD⁺-dependent sirtuins) on BRAF-mutant cancers and BRAF inhibitor resistance based on upregulated survival mechanisms and the prevention of tumor cell death. Moreover, it outlines reasonable HDAC-based strategies to circumvent BRAF-associated resistance mechanisms based on downregulated cell death mechanisms.

Keywords

Apoptosis / autophagy / BRAF-mutant cancer / drug resistance / histone deacetylase / melanoma / senescence / sirtuin

References

[1] Halle BR.Defining and targeting BRAF mutations in solid tumors.Curr Treat Options Oncol2021;22:30

[2] Pearson G,Beers Gibson T.Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.Endocr Rev2001;22:153-83

[3] Zhong J,Wang C.BRAF inhibitor resistance in melanoma: mechanisms and alternative therapeutic strategies.Curr Treat Options Oncol2022;23:1503-21 PMCID:PMC9596525

[4] Song Y,Liu Y,Wei Y.Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials.Genes Dis2023;10:76-88 PMCID:PMC10066287

[5] Degirmenci U,Sim YRM,Hu J.Drug resistance in targeted cancer therapies with RAF inhibitors.Cancer Drug Resist2021;4:665-83 PMCID:PMC9094075

[6] Biersack B,Höpfner M.Role and function of receptor tyrosine kinases in BRAF mutant cancers.Receptors2024;3:58-106

[7] Castellani G,Arasi MB.BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers.Cancers2023;15:4026 PMCID:PMC10452867

[8] Torres-Collado AX,Jazirehi AR.Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAF^V600E-specific inhibitor).Cancers2018;10:157 PMCID:PMC6025215

[9] Hanly A,Nocco S,Wu M.Drugging the epigenome: overcoming resistance to targeted and immunotherapies in melanoma.JID Innov2022;2:100090 PMCID:PMC8844701

[10] Zaib S,Khan I.Histone modifications and their role in epigenetics of cancer.Curr Med Chem2022;29:2399-411

[11] Patel AB,Radhakrishnan I.Histone acetylation and deacetylation - mechanistic insights from structural biology.Gene2024;890:147798 PMCID:PMC11253779

[12] Peng L.Deacetylation of nonhistone proteins by HDACs and the implications in cancer.Handb Exp Pharmacol2011;206:39-56

[13] Nebbioso A,Benedetti R.Trials with ‘epigenetic’ drugs: an update.Mol Oncol2012;6:657-82 PMCID:PMC5528349

[14] Biersack B,Höpfner M.HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.Cancer Drug Resist2022;5:64-79 PMCID:PMC8992583

[15] Biersack B,Höpfner M.Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: new chances for sophisticated drug design and treatment optimization.Semin Cell Dev Biol2024;154:286-94

[16] Yeon M,Jung HS.Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma.Front Cell Dev Biol2020;8:486 PMCID:PMC7311641

[17] Wee P.Epidermal growth factor receptor cell proliferation signaling pathways.Cancers2017;9:52 PMCID:PMC5447962

[18] Rushworth LK,O'Neill E.Regulation and role of Raf-1/B-Raf heterodimerization.Mol Cell Biol2006;26:2262-72 PMCID:PMC1430271

[19] Lovly CM,Fohn LE.Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.PLoS One2012;7:e35309 PMCID:PMC3335021

[20] Rubinstein JC,Pavlick AC.Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.J Transl Med2010;8:67 PMCID:PMC2917408

[21] Santarpia L,El-Naggar AK.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.Expert Opin Ther Targets2012;16:103-19 PMCID:PMC3457779

[22] Dankner M,Rajkumar S,Watson IR.Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.Oncogene2018;37:3183-99

[23] Allen A,Raj N.Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.PLoS One2019;14:e0217399 PMCID:PMC6546234

[24] Dai X,Yin Q.Acetylation-dependent regulation of BRAF oncogenic function.Cell Rep2022;38:110250 PMCID:PMC8813213

[25] Holderfield M,McCormick F.Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Nat Rev Cancer2014;14:455-67 PMCID:PMC4250230

[26] Garbe C.Vemurafenib. In: Martens UM, Editor. Small molecules in oncology. Cham: springer international publishing; 2018. pp. 77-89.

[27] Bowyer S,Fusi A.Dabrafenib and its use in the treatment of metastatic melanoma.Melanoma Manag2015;2:199-208 PMCID:PMC6094610

[28] Rose AAN.Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.Drugs Today2019;55:247-64

[29] Grothey A,Tabernero J.Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Ann Oncol2021;32:959-67

[30] Long GV,Gogas H.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N Engl J Med2014;371:1877-88

[31] Eriksen M,Rohrberg KS.A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.BMC Cancer2022;22:1321 PMCID:PMC9758813

[32] Long GV,Lo S.Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.Lancet Oncol2019;20:961-71

[33] Namikawa K.Targeted therapy and immunotherapy for melanoma in Japan.Curr Treat Options Oncol2019;20:7 PMCID:PMC6344396

[34] Okimoto RA,Olivas V.Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.Proc Natl Acad Sci USA2016;113:13456-61 PMCID:PMC5127364

[35] Kotani H,Kitai H.Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.Oncogene2018;37:1775-87

[36] Scardaci R,Scaparone P.Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Mol Oncol2024;18:1355-77 PMCID:PMC11161739

[37] Yin H,Xia H.Targeting RAF dimers in RAS mutant tumors: from biology to clinic.Acta Pharm Sin B2024;14:1895-923 PMCID:PMC11120325

[38] Biterge B.Histone variants: key players of chromatin.Cell Tissue Res2014;356:457-66

[39] Bannister AJ.Regulation of chromatin by histone modifications.Cell Res2011;21:381-95 PMCID:PMC3193420

[40] Wahi A,Jain P.Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer.Bioorg Chem2023;140:106833

[41] Milazzo G,Di Muzio G.Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability.Genes2020;11:556 PMCID:PMC7288346

[42] Singh BN,Hwa YL,Dowdy SC.Nonhistone protein acetylation as cancer therapy targets.Expert Rev Anticancer Ther2010;10:935-54 PMCID:PMC3273412

[43] Shanmugam G,Sarkar K.HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases.Transl Oncol2022;16:101312 PMCID:PMC8688863

[44] Hodgkinson K,Dobranowski P.Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease.Clin Nutr2023;42:61-75

[45] Göttlicher M,Zhu P.Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.EMBO J2001;20:6969-78 PMCID:PMC125788

[46] Mazzio EA.Whole-transcriptomic profile of SK-MEL-3 melanoma cells treated with the histone deacetylase inhibitor: trichostatin A.Cancer Genomics Proteomics2018;15:349-64 PMCID:PMC6199573

[47] Mcclure JJ,Chou CJ.Advances and challenges of HDAC inhibitors in cancer therapeutics. Elsevier; 2018. pp. 183-211.

[48] Sun Y,Ning Z.Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.Front Pharmacol2022;13:932914 PMCID:PMC9481063

[49] Pojani E.Selective inhibitors of histone deacetylase 10 (HDAC-10).Curr Med Chem2022;29:2306-21

[50] Kong D,Bao B,Banerjee S.Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.PLoS One2012;7:e45045 PMCID:PMC3443231

[51] Jenke R,Hansen FK,Büch T.Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives.Cancers2021;13:634 PMCID:PMC7915831

[52] Biersack B,Höpfner M.Anticancer properties of chimeric HDAC and kinase inhibitors.Semin Cancer Biol2022;83:472-86

[53] Li Y,Cheng H.Discovery of BRAF/HDAC dual inhibitors suppressing proliferation of human colorectal cancer cells.Front Chem2022;10:910353 PMCID:PMC9354042

[54] Wu QJ,Chen HH.The sirtuin family in health and disease.Signal Transduct Target Ther2022;7:402 PMCID:PMC9797940

[55] Sauve AA.Sirtuins: NAD⁺-dependent deacetylase mechanism and regulation.Curr Opin Chem Biol2012;16:535-43

[56] Dai H,Ellis JL.Sirtuin activators and inhibitors: promises, achievements, and challenges.Pharmacol Ther2018;188:140-54 PMCID:PMC6342514

[57] Süssmuth SD, Haider S, Landwehrmeyer GB, et al; PADDINGTON Consortium. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br J Clin Pharmacol. 2015;79:465-76. PMCID:PMC4345957

[58] Amengual JE,Kalac M.Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.Blood2013;122:2104-13

[59] Abaza A,Sadhu A.A systematic review of apoptosis in correlation with cancer: should apoptosis be the ultimate target for cancer treatment?.Cureus2022;14:e28496 PMCID:PMC9514374

[60] Tian X,Tajiknia V.Targeting apoptotic pathways for cancer therapy.J Clin Invest2024;134:e179570 PMCID:PMC11245162

[61] Sheridan C,Martin SJ.Oncogenic B-Raf^V600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.J Biol Chem2008;283:22128-35

[62] Letai A,Walensky LD,Weiler S.Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.Cancer Cell2002;2:183-92

[63] Kuwana T,Chipuk JE.BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.Mol Cell2005;17:525-35

[64] Chen L,Wei A.Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.Mol Cell2005;17:393-403

[65] Peng Z,Richter A,Schlaak MS.Effective targeting of melanoma cells by combination of Mcl-1 and Bcl-2/Bcl-x_L/Bcl-w Inhibitors.Int J Mol Sci2024;25:3453 PMCID:PMC10970841

[66] Hartman ML,Kluszczyńska K.Pro-apoptotic activity of MCL-1 inhibitor in trametinib-resistant melanoma cells depends on their phenotypes and is modulated by reversible alterations induced by trametinib withdrawal.Cancers2023;15:4799 PMCID:PMC10571954

[67] Kaplan FM,Mayberry MM.Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.Oncogene2011;30:366-71 PMCID:PMC6591715

[68] Fratta E,Guerrieri R.Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective.Cell Death Discov2023;9:202 PMCID:PMC10310793

[69] Leo L, Bodemeyer V, De Zio D. The complex role of autophagy in melanoma evolution: new perspectives from mouse models.Front Oncol2019;9:1506 PMCID:PMC6966767

[70] Liu X,Qin H.The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma.Target Oncol2018;13:437-46

[71] Li S,Quach C.Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance.Nat Commun2019;10:1693 PMCID:PMC6461621

[72] Verykiou S,Edwards N.Harnessing autophagy to overcome mitogen - activated protein kinase kinase inhibitor - induced resistance in metastatic melanoma.Br J Dermatol2019;180:346-56 PMCID:PMC7816093

[73] Xie X,Price S,Mehnert JM.Atg7 overcomes senescence and promotes growth of Braf^V600E-driven melanoma.Cancer Discov2015;5:410-23 PMCID:PMC4390491

[74] Xue G,Tang F.mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.Oncotarget2017;8:69204-18 PMCID:PMC5642473

[75] Nyakas M,Haugen MH.AXL inhibition improves BRAF-targeted treatment in melanoma.Sci Rep2022;12:5076 PMCID:PMC8948193

[76] Li Z,Zhu X.Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.Cancer Lett2016;370:332-44

[77] Liguoro D,Ortolano A.The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.Cell Death Dis2024;15:208 PMCID:PMC10933445

[78] Peng J,Chen W.Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance.Heliyon2023;9:e17714 PMCID:PMC10345356

[79] Lai F,Gallagher S,Zhang XD.Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Current challenges in personalized cancer medicine. Elsevier; 2012. pp. 27-43.

[80] Maertens O,Manchester HE.MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas.Cancer Discov2019;9:526-45 PMCID:PMC10151004

[81] Karagiannis D.HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity.Cancers2021;13:3575 PMCID:PMC8307174

[82] Ding G,Huang Q.HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.FEBS Lett2013;587:880-6

[83] Celesia A,Di Liberto D.Oncogenic BRAF and p53 interplay in melanoma cells and the effects of the HDAC inhibitor ITF2357 (Givinostat).Int J Mol Sci2023;24:9148 PMCID:PMC10252263

[84] Kim Y,Park D.Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs.J Biol Chem2010;285:25957-68 PMCID:PMC2923988

[85] Trost B,Chan AJS.Genomic architecture of autism from comprehensive whole-genome sequence annotation.Cell2022;185:4409-27.e18 PMCID:PMC10726699

[86] Jonas O,Kosciuk T.Parallel in vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities.Clin Cancer Res2016;22:6031-8 PMCID:PMC5320949

[87] Wang L,Huijberts S.An acquired vulnerability of drug-resistant melanoma with therapeutic potential.Cell2018;173:1413-25.e14

[88] Embaby A,Wang L.A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600-mutated melanoma.Clin Cancer Res2024;30:3157-66

[89] Shao Y.BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.Cell Death Differ2012;19:2029-39 PMCID:PMC3504716

[90] Gallagher SJ,Beaumont KA.HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.Int J Cancer2018;142:1926-37

[91] Borst A,Grimm J.BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.Cancer Lett2017;404:70-8

[92] Heinemann A,De Paoli-Iseppi R.Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.Oncotarget2015;6:21507-21 PMCID:PMC4673282

[93] Ha SD,Li SSC.HDAC8 activates AKT through upregulating PLCB1 and suppressing DESC1 expression in MEK1/2 inhibition-resistant cells.Cells2021;10:1101 PMCID:PMC8147860

[94] Emmons MF,Sharma R.HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy.Cancer Res2019;79:2947-61 PMCID:PMC6548652

[95] Wilmott JS,Kakavand H.Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.Mod Pathol2015;28:884-94

[96] Kobayashi Y,Murakami T.Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.Oncogene2006;25:512-24

[97] Carson R,Fenning C.HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL.Clin Cancer Res2015;21:3230-40 PMCID:PMC4504978

[98] Cheng J,Fang J.Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation.Nat Commun2015;6:7023 PMCID:PMC4432644

[99] Reu FJ,Cherkassky L.Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.J Clin Oncol2006;24:3771-9

[100] Gassenmaier M,Fehrenbacher B.Expression of DNA methyltransferase 1 is a hallmark of melanoma, correlating with proliferation and response to B-Raf and mitogen-activated protein kinase inhibition in melanocytic tumors.Am J Pathol2020;190:2155-64

[101] Dent P,Poklepovic A.Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.Pigment Cell Melanoma Res2022;35:66-77 PMCID:PMC11559083

[102] Lai F,Jin L.Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.Cell Death Dis2013;4:e655 PMCID:PMC3702278

[103] Biran A,Haklai R.Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.Int J Cancer2011;128:691-701

[104] Booth L,Sander C.The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.Oncotarget2017;8:16367-86 PMCID:PMC5369969

[105] Booth L,Von Hoff D,Dent P.GZ17-6.02 interacts with [MEK1/2 and B-RAF inhibitors] to kill melanoma cells.Front Oncol2021;11:656453 PMCID:PMC8061416

[106] Ling H,Peng C,Seto E.HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression.NAR Cancer2024;6:zcae018 PMCID:PMC11034028

[107] Fan TM.Exploring the potential utility of pet dogs with cancer for studying radiation-induced immunogenic cell death strategies.Front Oncol2018;8:680 PMCID:PMC6340932

[108] Miao Y.Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy.J Nucl Med2021;62:313-8 PMCID:PMC8049342

[109] Li M,Lee D.Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma.Mol Pharm2019;16:3904-15 PMCID:PMC6765223

[110] Cui Y,Cao L.Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity.Nat Commun2023;14:5740 PMCID:PMC10504282

[111] Fu H,Jin Y,Liu M.MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAF^V600E: an in vitro study.Mol Ther Oncolytics2019;12:235-45 PMCID:PMC6389779

[112] Cheng W,Zhu G,Xing M.Robust thyroid gene expression and radioiodine uptake induced by simultaneous suppression of BRAF V600E and histone deacetylase in thyroid cancer cells.J Clin Endocrinol Metab2016;101:962-71 PMCID:PMC4803151

[113] Madorsky Rowdo FP,Gallagher SJ.Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive longterm BRAF inhibition.Int J Oncol2020;56:1429-41 PMCID:PMC7170042

[114] Heijkants R,Schoonderwoerd M.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Oncotarget2018;9:6174-87 PMCID:PMC5814203

[115] Granieri L,Melixetian M.Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors.Cell Rep2022;40:111396

[116] Woods DM,Villagra A,Sotomayor EM.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade.Cancer Immunol Res2015;3:1375-85 PMCID:PMC4674300

[117] López-Cobo S,Campos-Silva C.Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.Oncoimmunology2018;7:e1392426 PMCID:PMC5749663

[118] Hegedűs L,Garay T.HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line.Pathol Oncol Res2020;26:2523-35 PMCID:PMC7471186

[119] Woan KV,Perez-Villaroel P.Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation.Mol Oncol2015;9:1447-57 PMCID:PMC4523430

[120] Knox T,Banik D.Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.Sci Rep2019;9:6136 PMCID:PMC6467894

[121] Noonepalle SKR,Aghdam N.Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma.J Exp Clin Cancer Res2024;43:263 PMCID:PMC11401321

[122] Gracia-Hernandez M,Gajendran N.Targeting HDAC6 improves anti-CD47 immunotherapy.J Exp Clin Cancer Res2024;43:60 PMCID:PMC10898070

[123] Noonepalle S,Ptáček J.Rational design of suprastat: a novel selective histone deacetylase 6 inhibitor with the ability to potentiate immunotherapy in melanoma models.J Med Chem2020;63:10246-62

[124] Tavares MT,Knox T.Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models.ACS Med Chem Lett2017;8:1031-6 PMCID:PMC5641951

[125] Shen S,Ustinova K.Discovery of a new isoxazole-3-hydroxamate-based histone deacetylase 6 inhibitor ss-208 with antitumor activity in syngeneic melanoma mouse models.J Med Chem2019;62:8557-77

[126] Kovalovsky D,Suresh M.The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy.Sci Adv2024;10:eadp3687 PMCID:PMC11566997

[127] Peng X,Chen J.Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma.J Med Chem2022;65:2434-57

[128] Tsimberidou AM,Cartwright CA.Preclinical development and First-in-Human study of KA2507, a selective and potent inhibitor of histone deacetylase 6, for patients with refractory solid tumors.Clin Cancer Res2021;27:3584-94

[129] Bajpe PK,Horlings H,Beijersbergen R.A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.Oncogene2015;34:531-6

[130] Ohanna M,Bille K.SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells.Oncotarget2014;5:2085-95 PMCID:PMC4039147

[131] George J,Singh CK.4’-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming.Mol Carcinog2019;58:1876-85 PMCID:PMC6721992

[132] Chhabra G,Guzmán-Pérez G,Iczkowski KA.Antimelanoma effects of concomitant inhibition of SIRT1 and SIRT3 in Braf^V600E/Pten^NULL mice.J Invest Dermatol2022;142:1145-57.e7 PMCID:PMC9199498

[133] Sun T,Wang Y,Ming L.SIRT1 induces epithelial-mesenchymal transition by promoting autophagic degradation of E-cadherin in melanoma cells.Cell Death Dis2018;9:136 PMCID:PMC5833732

[134] Kriegl L,Kirchner T.Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer.Oncotarget2012;3:1182-93 PMCID:PMC3717960

[135] Brandl L,Neumann J.The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.Med Oncol2018;36:5

[136] Brandl L,Kirstein N.Targeting c-MYC through interference with NAMPT and SIRT1 and their association to oncogenic drivers in murine serrated intestinal tumorigenesis.Neoplasia2019;21:974-88 PMCID:PMC6710297

[137] Garcia-Peterson LM.Trending topics of SIRT1 in tumorigenicity.Biochim Biophys Acta Gen Subj2021;1865:129952 PMCID:PMC8277705

[138] Dumaz N,Martin J.In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.Cancer Res2006;66:9483-91

[139] Mehrabipour M,Dvorsky R.SIRT4 as a novel interactor and candidate suppressor of C-RAF kinase in MAPK signaling.Life Sci Alliance2024;7:e202302507 PMCID:PMC10948936

[140] Giblin W,Guo AH.The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.J Clin Invest2021;131:138926 PMCID:PMC8203465

[141] Moon H,White AC.Sirt5 is dispensable for Braf^V600E -mediated cutaneous melanoma development and growth in vivo.Exp Dermatol2019;28:83-5

[142] Strub T,Carcamo S.SIRT6 haploinsufficiency induces BRAF^V600E melanoma cell resistance to MAPK inhibitors via IGF signalling.Nat Commun2018;9:3440 PMCID:PMC6109055

[143] Qu N,Liu L.SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl1 pathway.Int J Oncol2017;50:1683-92

[144] Wang L,Ma J.Aberrant SIRT6 expression contributes to melanoma growth: role of the autophagy paradox and IGF-AKT signaling.Autophagy2018;14:518-33 PMCID:PMC5915046

[145] Baran M,Stepulak A.The role of Sirtuin 6 in the deacetylation of histone proteins as a factor in the progression of neoplastic disease.Int J Mol Sci2023;25:497 PMCID:PMC10779230

[146] Du J,Guo S.SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma.Biochem Biophys Res Commun2024;722:150161

[147] Yi X,Yang Y.SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR activation.Signal Transduct Target Ther2023;8:107 PMCID:PMC10015075

[148] Ianni A,Tarighi S,Vaquero A.SIRT7: a novel molecular target for personalized cancer treatment?.Oncogene2024;43:993-1006 PMCID:PMC10978493